Literature DB >> 8233388

Flexible open-loop anterior chamber intraocular lens implants.

L E Weene.   

Abstract

PURPOSE: To determine the efficacy of flexible open-loop anterior chamber intraocular lens (AC IOL) implants in cataract surgery complicated by vitreous loss and in secondary implantation.
METHOD: Results were reviewed in 18 eyes in the former group and in 43 eyes in the latter group that were operated on by the author over an 8-year period.
RESULTS: Of 18 eyes in the former group, 13 (72%) had a final visual acuity of 20/40 or better. Cystoid macular edema was the most common cause of the decrease in visual acuity. Of 43 eyes in the latter group, 37 (86%) had a final vision equal to the best-corrected preoperative vision. A retinal complication developed in 6 of 18 eyes that received a primary AC IOL with vitreous loss, whereas no retinal complications developed in any of the 14 eyes that received a secondary AC IOL with vitreous loss (P = 0.021). For secondary AC IOL implantation, eyes with vitreous loss treated by Weck-cel sponge vitrectomy had the same visual results as eyes without vitreous loss.
CONCLUSION: Flexible open-loop AC IOLs are safe and effective for primary implantation after vitreous loss and for secondary implantation.

Entities:  

Mesh:

Year:  1993        PMID: 8233388     DOI: 10.1016/s0161-6420(13)31445-6

Source DB:  PubMed          Journal:  Ophthalmology        ISSN: 0161-6420            Impact factor:   12.079


  11 in total

1.  [History of the development of intraocular lenses].

Authors:  G U Auffarth; D J Apple
Journal:  Ophthalmologe       Date:  2001-11       Impact factor: 1.059

2.  Visual outcomes after anterior vitrectomy: comparison of ECCE and phacoemulsification.

Authors:  J C Bobrow
Journal:  Trans Am Ophthalmol Soc       Date:  1999

3.  Comparision of surgical outcomes of intraocular lens refixation and intraocular lens exchange with perfluorocarbon liquid and fibrin glue-assisted sutureless scleral fixation.

Authors:  S Y Oh; S J Lee; J M Park
Journal:  Eye (Lond)       Date:  2015-03-20       Impact factor: 3.775

4.  Secondary Posterior Chamber Intraocular Lens Fixation Using Flanged Prolene Sutures as an Alternative to an Anterior Chamber Intraocular Lens Implantation.

Authors:  Avner Hostovsky; Mark Mandelcorn; Efrem D Mandelcorn
Journal:  Clin Ophthalmol       Date:  2020-10-23

5.  Refractive errors after sutureless intrascleral fixation of intraocular lens.

Authors:  Masato Kakisu; Takayuki Baba; Tomoaki Tatsumi; Takehito Iwase; Tomohiro Nizawa; Gen Miura; Shuichi Yamamoto
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2021-06-18       Impact factor: 3.117

6.  Role of ultrasound biomicroscopy in the planning for secondary implantation of intra ocular lens in aphakia.

Authors:  Mohamed Elfiky; Hisham Saad; Rabab Elseht; Adel Selima
Journal:  Int Ophthalmol       Date:  2015-10-22       Impact factor: 2.031

7.  Air-assisted descemet stripping automated endothelial keratoplasty with posterior chamber fixation of an aphakic iris-claw lens.

Authors:  Farid Karimian; Mohammad-Mehdi Sadoughi
Journal:  J Ophthalmic Vis Res       Date:  2010-07

8.  Five-year follow-up of secondary iris-claw intraocular lens implantation for the treatment of aphakia: Anterior chamber versus retropupillary implantation.

Authors:  Mario Damiano Toro; Antonio Longo; Teresio Avitabile; Katarzyna Nowomiejska; Caterina Gagliano; Sarah Tripodi; Tomasz Choragiewicz; Agnieszka Kaminska; Michele Figus; Chiara Posarelli; Matteo Forlini; Anselm Gerhard Maria Jünemann; Michele Reibaldi; Robert Rejdak
Journal:  PLoS One       Date:  2019-04-10       Impact factor: 3.240

9.  Secondary IOL Implantation without Capsular Support: A Laser Flare Cell Meter Study.

Authors:  Mauro Cellini; Ernesto Strobbe; Pier Giorgio Toschi; Emilio C Campos
Journal:  ISRN Ophthalmol       Date:  2012-01-02

10.  Retropupillary iris-claw intraocular lens implantation in aphakic patients.

Authors:  C V Sumitha; Vijay Pai; Mithun Thulasidas
Journal:  Indian J Ophthalmol       Date:  2020-04       Impact factor: 1.848

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.